The challenges and strategies for navigating in vivo barriers to therapeutic bacterial delivery
Abstract
Bacteria have emerged as promising living therapeutics for the treatment of infections, inflammatory disorders, metabolic diseases, and neoplastic diseases. However, their clinical efficacy is often compromised by in vivo barriers that reduce their viability and impair their function after administration. Rational engineering can help them sustain their viability under a harsh microenvironment and enhance their targetability as well as retention, ultimately improving their functional performance in vivo. This review starts with a concise synopsis of current status in live bacterial therapy, with particular emphasis on the major biological barriers to their in vivo application. Engineering strategies for harnessing bacterial intrinsic characteristics and overcoming their specific barriers are discussed. Representative examples are then presented to illustrate how engineered live bacteria overcome these biological barriers and achieve therapeutic applications via oral, topical, intravenous, and inhalational administration. Finally, we identify the key challenges associated with translating laboratory advances into reliable and safe clinical therapeutics.
How strong is the evidence?
Evidence Hub reads this as a review, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.